Pharmacologic Considerations in the Treatment of Major Depressive Disorder Presented by: Ann M. Hamer, PharmD, BCPP Date: 10/30/2014 Disclosures and Learning Objectives • Learning Objectives – – – Be able to identify common adverse effects of newer antidepressants Be able to discuss differences between the newer antidepressants Be able to define the goals of antidepressant treatment Disclosures: Dr. Ann Hamer has nothing to disclose. Pharmacologic Treatment of MDD • • • • • • Review summary of evidence Review adverse effects Review antidepressant withdrawal Review drug interactions Review antidepressant costs Review goals of treatment • Next Week's Topic Treatment Guidelines American Psychiatric Association Choosing an Initial Antidepressant Because there is comparable efficacy between and within classes of medications, the initial selection of antidepressants is based largely on the following considerations: •Anticipated side effects •Safety and tolerability of side effects for individual patients •Patient preference •Quantity and quality of clinical trial data •Cost www.psych.org OHSU Drug Effectiveness Review Project—CEBP Summary of the Evidence • Effectiveness and efficacy were similar between all second generation antidepressants. • Roughly a 60% overall response rate • Discontinuation rates and response and remission rates did not differ substantially. www.ohsu.edu/drugeffectiveness/reports/final.cfm Available Antidepressants SSRIs Brintellix (vortioxetine) B Celexa (citalopram) G Lexapro (escitalopram) G Luvox (fluvoxamine) G Paxil (paroxetine) G Prozac (fluoxetine) G Viibryd (vilazodone) B Zoloft (sertraline) G Selectively inhibit the reuptake of serotonin (5HT) at the presynaptic neuronal membrane G=Generic; B=Brand SNRIs Cymbalta (duloxetine) B Effexor (venlafaxine) G Fetzima (levomilnacipran) B Pristiq (desvenlafaxine) B Others Wellbutrin (bupropion) G Bupropion is a weak inhibitor of DA, NE and 5HT reuptake Remeron (mirtazapine) G Inhibit serotonin and norepinephrine reuptake Mirtazapine ↑central noradrenaline and 5HT activity by antagonizing central presynaptic α2 adrenergic autoreceptors and heteroreceptors Common Adverse Effects SNRIs SSRIs • • • • • • • Nausea Vomiting Dizziness Insomnia Agitation Headache Sexual dysfunction • • • • • • • • • Nausea Vomiting Dizziness Insomnia Anxiety Headache Somnolence Decreased appetite Sexual dysfunction Others Bupropion: • Headache • Agitation, • Weight loss • Insomnia • Nausea Mirtazapine: • Dizziness • Diarrhea • Increased appetite (weight gain) • Drowsiness, • Dry mouth ATD Induced Sexual Dysfunction Antidepressant Type of Sexual Dysfunction Incidence* Venlafaxine Impaired ejaculation, delayed/absent orgasm 12% Paroxetine Impaired ejaculation, delayed/absent orgasm 13-28% Fluvoxamine Impaired ejaculation, delayed/absent orgasm 2-8% Sertraline Impaired ejaculation, delayed/absent orgasm 14% Citalopram Impaired ejaculation, delayed/absent orgasm, decreased libido 1-6% Fluoxetine Impaired ejaculation, delayed/absent orgasm, decreased libido, and erectile impairment 2-11% Mirtazapine Decreased libido 2-6% Bupropion Decreased libido 1-3% *Based on spontaneous report in clinical trials ATD Induced Sexual Dysfunction Key Points • Serotonergic antidepressant incidence may be as high as 50-70%. • Lowest level of sexual dysfunction with nonserotonergic antidepressants. • Patients should be routinely asked about sexual adverse effects. May affect ATD adherence. • Best way to avoid is the use of nonserotonergic antidepressants. ATD Sexual Dysfunction Treatment • Use non-serotonergic antidepressant (e.g. bupropion) first. • Wait it out • Only useful in a minority of patients • Carefully switch to non-serotonergic antidepressant Drug Interactions Drug Interactions • Citalopram—least likely SSRI to cause CYP450 drug interactions • Venlafaxine—less likely than duloxetine to cause drug interactions; duloxetine more highly protein bound and 1A2 substrate • Bupropion—can lower the seizure threshold ATD Withdrawal Occurs with most antidepressants if the dose is not tapered. Serotonin discontinuation syndrome F = flu-like symptoms I = insomnia N = nausea I = imbalance S = sensory disturbances H = hyperarousal ATD Withdrawal • May be difficult to distinguish from depression relapse. • Antidepressant withdrawal syndrome is characterized by the time-locked emergence of new, defined and quantifiable signs and symptoms, which develop on cessation or reduction of an antidepressant that has been taken for more than a few weeks. ATD Withdrawal Symptoms • • • Typically start 24 to 72 hours after the last antidepressant dose (peaking at 1 week). Typically resolve within 1 to 3 weeks. Severe and disabling withdrawal syndrome seen in 5% of patients. Treatment • • • Tapering the dose can decrease the symptoms. Restarting the antidepressant will make the symptoms go away. Slower tapers may then be necessary • Depends on drug and patient Patient Preference Patient Responses Common Side Effects Precautions MD experience Uncommon serious s.e. DC problems Time in market Dosing schedule Cost Blood test Common other uses Pill appearance GP Responses Common side effects Cost Precautions MD experience Dosing schedule DC problems Uncommon serious s.e. Time in market Blood test Common other uses Pill appearance Antidepressants Costs Drug Average Dose Average Cost* Comment Brintellix (vortioxetine) 20mg QD $253 Brand only Bupropion XL 150mg BID $28 Citalopram 20mg QD $5 LCA, $ Cymbalta (duloxetine) 30mg QD $39 Brand only Escitalopram 10mg QD $12 Fetzima (levomilnacipran) 40mg QD $201 Brand only Fluoxetine 20mg QD $5 LCA Fluvoxamine 100mg BID $14 Mirtazapine 30mg QD $13 Paroxetine 20mg QD $9 LCA, $ Pristiq (desvenlafaxine) 100mg QD $157 Brand only Sertraline 100mg QD $9 LCA Venlafaxine XR 150mg QD $17 Viibryd (vilazodone) 40mg QD $176 Brand only *GoodRx.com price comparison; LCA=low cost alternative; $=Walmart $4/$10 generic Defining the Goals of Treatment Response = a clinically significant degree of depressive symptom reduction following treatment initiation. When used clinically, response implies that the treatment has caused the response Response criteria must be met for 3 consecutive weeks Remission = the virtual absence of depressive symptoms. 3 consecutive weeks must pass, during which each week is characterized by the virtual absence of depressive symptoms, before remission can be ascribed. Remission may end with either relapse or recovery. Progressive ATD Treatment (STAR*D) Level Treatment Choices 1 Monotherapy 2 3 4 Remission Rate Relapse Rate SSRI 30% 33.5% Switch Different SSRI, bupropion SR or venlafaxine XR 25% 47.4% Augment Bupropion SR 30% Switch Mirtazapine or nortriptyline Augment Lithium or thyroid (T3) Switch MAOI or venlafaxine + mirtazapine 12-20% 42.9% 16% 25% 6.9% 13.7% >50% Switching Strategies Drug switching to Initial drug Fluoxetine Other SSRI SNRI Mirtazapine Nefazodone Bupropion MAOI Fluoxetine 3 1 2 3 1 3 Other SSRI 1 1 1 2 3 2 3 SNRI 1 1 1 2 2 2 3 Mirtazapine 2 2 2 2 2 3 Nefazodone 3 3 2 2 2 3 Bupropion 1 1 1 2 2 3 MAOI 3 3 3 3 3 3 Key: (1) direct switch probably safe; (2) cross-taper recommended; (3) washout period advisable ATD Comparison Summary of Comparative Data with Newer ATDs (Moderate to High Level Evidence) Comparative Benefits •Similar efficacy, effectiveness, and QOL •Onset of action •Mirtazapine > citalopram, fluoxetine, paroxetine, & sertraline •Response rates similar after 4 weeks of tx Comparative Adverse Effects •Nausea and vomiting: Venlafaxine has a 52% higher incidence than SSRIs as a class •Weight gain: Mirtazapine > citalopram, fluoxetine, paroxetine, sertraline (1.8 – 6.6 lbs after 6-8 wks) •Efficacy does not differ in older adults •Diarrhea: Sertraline > bupropion, citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine & venlafaxine •Fluoxetine daily = fluoxetine weekly (response and remission rates) •Discontinuation Rates: Duloxetine & venlafaxine > SSRIs •Paroxetine IR = paroxetine CR (response and adherence rates) •Withdrawal Symptoms: Paroxetine & venlafaxine > other SSRIs; Lowest with fluoxetine •Remission rates similar •Similar efficacy for treating anxiety and depression in MDD with anxiety sx •Paroxetine=duloxetine (pain scores for patients with depression •Sexual Dysfunction: Bupropion < escitalopram, fluoxetine, paroxetine, and sertraline; Paroxetine > other SSRIs Summary • Best chance for success (remission) with antidepressant tx may be with first trial • • Use at an adequate dose for an adequate duration Similar efficacy between newer antidepressants with minor differences • Adverse effects, drug interactions, patient preference and cost are all important considerations The End! Next Week's Topic: Pharmacologic Treatment of Bipolar Disorder